Mauras N
Department of Pediatrics, Nemours Children's Clinic, Jacksonville, Florida 32207, USA.
J Clin Endocrinol Metab. 1995 Sep;80(9):2633-7. doi: 10.1210/jcem.80.9.7673406.
Recent data demonstrate that recombinant human insulin-like growth factor I (rhIGF-I) has GH-like effects on protein metabolism, selectively stimulating whole body protein synthesis. Additionally, recent studies suggest that the combination of recombinant human GH (rhGH) and rhIGF-I might be more anabolic than either compound alone when administered to calorically deprived subjects. To investigate whether the same is true in normally fed healthy individuals, seven healthy subjects (mean age, 26 +/- 1 yr) fed a normal weight maintenance diet (approximately 33 Cal/kg.day) with approximately 1.4 g/kg.day protein were given rhGH (0.025 mg/kg.day) and rhIGF-I (100 micrograms/kg bid daily) sc for 5 days. Whole body leucine kinetics were studied using primed 4-h infusions of [14C]leucine before and after treatment and measuring the specific activity of 14C-labeled alpha-ketoisocaproic acid and 14CO2 in plasma and breath, respectively. These data were compared with those from six additional subjects treated only with rhGH as well as with those from previously reported subjects given rhIGF-I alone. Subjects receiving combination treatment had a significant increase in plasma IGF-I concentrations (123 +/- 9 to 709 +/- 29 micrograms/L; P = 0.001). As expected, there was a significant decrease in leucine oxidation in subjects given combination therapy (P = 0.03) as well as a significant increase in leucine turnover (P = 0.018); hence the nonoxidative leucine disposal, a measure of whole body protein synthesis, was significantly increased (P = 0.018). However, when the absolute changes in all three parameters of leucine kinetics were compared in the three treatment groups (rhGH alone, rhIGF-I alone, and combined rhGH and rhIGF-I), there was no additive effect of combination treatment on whole body protein anabolism (P > 0.05, by analysis of variance). We conclude that, contrary to the calorically deprived model, in normally fed individuals, the coadministration of rhIGF-I and rhGH at these doses is not more anabolic on whole body protein than either compound given alone. This difference in observed effects in the fed and partly fasted state may be related to the difference in total insulin output and suggests a saturable capacity of the body to accumulate protein during normal substrate availability while the body is exposed to individual anabolic hormones. These data suggest a common pathway for GH and IGF-I to enhance whole body protein anabolism in the normally fed state.
近期数据表明,重组人胰岛素样生长因子I(rhIGF-I)对蛋白质代谢具有类生长激素(GH)样作用,可选择性刺激全身蛋白质合成。此外,近期研究表明,对热量摄入不足的受试者给予重组人生长激素(rhGH)和rhIGF-I联合使用时,其合成代谢作用可能比单独使用任一化合物更强。为研究在正常进食的健康个体中情况是否相同,选取7名健康受试者(平均年龄26±1岁),给予其正常体重维持饮食(约33千卡/千克·天),蛋白质摄入量约为1.4克/千克·天,皮下注射rhGH(0.025毫克/千克·天)和rhIGF-I(100微克/千克,每日两次),持续5天。在治疗前后分别通过静脉注射[14C]亮氨酸4小时,并测量血浆和呼出气体中14C标记的α-酮异己酸和14CO2的比活度,研究全身亮氨酸动力学。将这些数据与另外6名仅接受rhGH治疗的受试者以及之前报道的仅接受rhIGF-I治疗的受试者的数据进行比较。接受联合治疗的受试者血浆IGF-I浓度显著升高(从123±9微克/升升至709±29微克/升;P = 0.001)。正如预期的那样,联合治疗的受试者亮氨酸氧化显著降低(P = 0.03),亮氨酸周转率显著升高(P = 0.018);因此,作为全身蛋白质合成指标的非氧化亮氨酸处置量显著增加(P = 0.018)。然而,当比较三个治疗组(单独使用rhGH、单独使用rhIGF-I以及联合使用rhGH和rhIGF-I)中亮氨酸动力学所有三个参数的绝对变化时,联合治疗对全身蛋白质合成代谢没有相加作用(方差分析,P>0.05)。我们得出结论,与热量摄入不足模型相反,在正常进食的个体中,以这些剂量联合使用rhIGF-I和rhGH对全身蛋白质的合成代谢作用并不比单独使用任一化合物更强。在进食和部分禁食状态下观察到的这种效应差异可能与总胰岛素分泌量的差异有关,这表明在正常底物供应情况下,当身体暴露于单独的合成代谢激素时,身体积累蛋白质的能力是可饱和的。这些数据表明,在正常进食状态下,GH和IGF-I通过共同途径增强全身蛋白质合成代谢。